CRISP3

Summary

CRISP3 (cysteine rich secretory protein 3, HGNC:16904) is a protein-coding gene on chromosome 6p12.3, encoding Cysteine-rich secretory protein 3 (P54108).

This gene encodes a member of the cysteine-rich secretory protein (CRISP) family within the CRISP, antigen 5 and pathogenesis-related 1 proteins superfamily. The encoded protein has an N-terminal CRISP, antigen 5 and pathogenesis-related 1 proteins domain, a hinge region, and a C-terminal ion channel regulator domain. This protein contains cysteine residues, located in both the N- and C-terminal domains, that form eight disulfide bonds, a distinguishing characteristic of this family. This gene is expressed in the male reproductive tract where it plays a role in sperm function and fertilization, and the female reproductive tract where it plays a role in endometrial receptivity for embryo implantation. This gene is upregulated in certain types of prostate cancer. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10321 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 43 total
• MANE Select transcript: NM_006061

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16904
Approved symbol	CRISP3
Name	cysteine rich secretory protein 3
Location	6p12.3
Locus type	gene with protein product
Status	Approved
Aliases	SGP28, CRISP-3, CRS3, dJ442L6.3, Aeg2
Ensembl gene	ENSG00000096006
Ensembl biotype	protein_coding
OMIM	618062
Entrez	10321

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000263045, ENST00000354620, ENST00000371159, ENST00000433368

RefSeq mRNA: 3 — MANE Select: NM_006061 NM_001190986, NM_001368123, NM_006061

CCDS: CCDS4929, CCDS55019, CCDS93932

Canonical transcript exons

ENST00000263045 — 8 exons

Exon	Start	End
ENSE00000850440	49727376	49728857
ENSE00001138750	49731163	49731251
ENSE00001138761	49733195	49733292
ENSE00002219370	49744331	49744388
ENSE00002311210	49737325	49737398
ENSE00002486518	49736391	49736507
ENSE00002488442	49733703	49733848
ENSE00003648010	49735504	49735591

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 99.67.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 10.0421 / max 4077.1644, expressed in 152 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73923	8.6927	115
73922	0.8319	45
73924	0.3006	42
73925	0.1617	29
73926	0.0552	15

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.67	gold quality
right uterine tube	UBERON:0001302	99.54	gold quality
lower esophagus mucosa	UBERON:0035834	98.94	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.83	gold quality
trabecular bone tissue	UBERON:0002483	98.57	gold quality
pharyngeal mucosa	UBERON:0000355	98.43	gold quality
tongue squamous epithelium	UBERON:0006919	98.28	gold quality
bone marrow	UBERON:0002371	98.04	gold quality
minor salivary gland	UBERON:0001830	97.83	gold quality
seminal vesicle	UBERON:0000998	97.63	gold quality
oral cavity	UBERON:0000167	97.54	gold quality
bone marrow cell	CL:0002092	97.43	gold quality
saliva-secreting gland	UBERON:0001044	96.35	gold quality
esophagus squamous epithelium	UBERON:0006920	96.28	gold quality
buccal mucosa cell	CL:0002336	96.15	gold quality
mouth mucosa	UBERON:0003729	96.04	gold quality
epithelium of esophagus	UBERON:0001976	95.68	gold quality
oviduct epithelium	UBERON:0004804	95.07	gold quality
bone element	UBERON:0001474	94.80	gold quality
trachea	UBERON:0003126	93.36	gold quality
cervix epithelium	UBERON:0004801	93.27	gold quality
cervix squamous epithelium	UBERON:0006922	92.85	gold quality
body of tongue	UBERON:0011876	92.78	gold quality
urethra	UBERON:0000057	92.44	gold quality
amniotic fluid	UBERON:0000173	92.22	gold quality
upper leg skin	UBERON:0004262	91.89	gold quality
esophagus mucosa	UBERON:0002469	91.20	gold quality
epithelial cell of pancreas	CL:0000083	90.91	gold quality
fallopian tube	UBERON:0003889	90.44	gold quality
tongue	UBERON:0001723	90.03	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	6220.75
E-HCAD-1	yes	11.54
E-ANND-3	yes	10.31

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, ERG, HOXC13, POU2F1, POU2F2

miRNA regulators (miRDB)

54 targeting CRISP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-508-5P	99.41	64.25	1248
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-520E-5P	99.27	68.90	1513

Literature-anchored findings (GeneRIF, showing 26)

• The presence of CRISP-3 in peroxidase-negative granules of neutrophils, in granules of eosinophils, and in exocrine secretions indicates a role in the innate host defense. (PMID:12223513)
• in situ hybridization experiments indicated that CRISP-3 mRNA is epithelial-specific and is up-regulated in prostate adenocarcinoma compared with benign prostate tissue; a potential biomarker for prostate cancer (PMID:12433721)
• high levels of CRISP-3 in acinar cells dedifferentiating into small proliferating ductal cells in chronic pancreatitis suggests a role of this molecule in the pathophysiology of chronic pancreatitis (PMID:12647793)
• alpha-1-B glycoprotein-CRISP-3 complex displays a similar function in protecting the circulation from a potentially harmful effect of free CRISP-3 (PMID:15461460)
• Human CRISP-3 is a quantitatively minor seminal plasma protein not associated with prostasomes. CRISP-3 was found in secretory epithelium throughout the male genital tract, with particularly high expression in cauda epididymis and ampulla vas deferens. (PMID:15867000)
• Structural similarity with an MSP-binding protein from blood plasma suggests that CRISP-3 binds MSP through its aminoterminal SCP-domain. (PMID:15950934)
• Strong immunostaining for CRISP-3 is common in high-grade prostatic-intraepithelial-neoplasia and preserved in prostatic csncer. (PMID:16388501)
• Predictor of recurrence after radical prostatectomy for localized prostate cancer. (PMID:17634540)
• CRISP-3 pathology occurred in acini remote from lymphocyte foci and may represent some systemic effect in Sjogren Syndrome. (PMID:17665393)
• A tentative structure for the hMSP-CRISP-3 complex using the known crystal structure of triflin as a model of CRISP-3 was presented. (PMID:19026612)
• Results suggest that absence of a local reduction in expression of CRISP-3 in decidualized endometrium of women with EP may be due to reduced exposure to hCG due to the ectopic location of the trophoblast. (PMID:19282327)
• Complex binding of CRISP proteins by A1BG and other proteins may interfere with the detection and function of these proteins. (PMID:20116414)
• Additional transcription changes likely associated with Th2-like eosinophilic inflammation were prominent and included decreased CRISP2&3. (PMID:20625511)
• Either PSP94 or CRISP-3 alone can induce growth inhibition in prostate cancer cells in a cell line specific manner. (PMID:20676114)
• Expression levels of AR and CRISP3 were not affected by short-term ADT but were high in castration-resistant prostate cancer (CRPC) and metastases. (PMID:20680031)
• We found no correlation between CRISP3 expression and biochemical recurrence. (PMID:21240253)
• up-regulation of CRISP3 is associated with prostate carcinomas with the TMPRSS2-ERG fusion gene. (PMID:21814574)
• MSMB and CRISP3 were widely distributed in ovaries and in ovarian tumors; the expression of MSMB fits well with a tumor-suppressor function in ovarian carcinogenesis. (PMID:22993349)
• Strong CRISP3 expression is associated with unfavorable tumor phenotype and early recurrence in prostate cancers (PMID:23196798)
• terminal beta-strands of PSP94 contact the first alpha-helix and the hinge region of CRISP-3 (PMID:23375721)
• up-regulation of the mRNA encoding cysteine-rich secretory protein 3 (CRISP3), a glycoprotein with unknown function that is secreted from multiple exocrine glands, was correlated with HCV resistance. (PMID:24978310)
• These data suggest roles for epithelial and neutrophil-derived CRISP3 in postmenstrual endometrial repair and regeneration (PMID:25715794)
• results suggest that overexpression of CRISP-3 in prostate tumor may maintain higher PSA expression and lower ANXA1 expression (PMID:26369530)
• in the presence of varicocoele, there is a marked increase in seminal CRISP-3 levels. Surgical intervention (varicocelectomy) decreases CRISP-3 levels and improves semen quality. (PMID:30354034)
• In this study, we found obvious differences in the expression of CRISP3 between different mammary carcinoma cells, which is related to the prognosis of patients with mammary carcinoma (PMID:30609035)
• EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer. (PMID:38879857)

Cross-species orthologs

47 orthologs

Organism	Symbol	Gene ID
mus_musculus	Crisp1	ENSMUSG00000025431
mus_musculus	Crisp3	ENSMUSG00000025433
rattus_norvegicus	Crisp3	ENSRNOG00000013496
drosophila_melanogaster	Ag5r	FBGN0015010
drosophila_melanogaster	Ag5r2	FBGN0020508
drosophila_melanogaster	CG9400	FBGN0030562
drosophila_melanogaster	CG10651	FBGN0032853
drosophila_melanogaster	CG9822	FBGN0034623
drosophila_melanogaster	CG17974	FBGN0034624
drosophila_melanogaster	CG3640	FBGN0035042
drosophila_melanogaster	CG8072	FBGN0036070
drosophila_melanogaster	CG6628	FBGN0036072
drosophila_melanogaster	scpr-C	FBGN0037879
drosophila_melanogaster	scpr-B	FBGN0037888
drosophila_melanogaster	scpr-A	FBGN0037889
drosophila_melanogaster	CG8483	FBGN0038126
drosophila_melanogaster	CG30486	FBGN0050486
drosophila_melanogaster	antr	FBGN0050488
drosophila_melanogaster	CG31286	FBGN0051286
drosophila_melanogaster	CG32313	FBGN0052313
drosophila_melanogaster	CG32679	FBGN0052679
drosophila_melanogaster	CG34002	FBGN0054002
drosophila_melanogaster	CG17575	FBGN0250842
drosophila_melanogaster	CG42564	FBGN0260766
drosophila_melanogaster	CG42780	FBGN0261848
drosophila_melanogaster	CG43775	FBGN0264297
drosophila_melanogaster	CG43776	FBGN0264298
drosophila_melanogaster	CG43777	FBGN0264299
caenorhabditis_elegans		WBGENE00004742
caenorhabditis_elegans		WBGENE00007397
caenorhabditis_elegans		WBGENE00008027
caenorhabditis_elegans		WBGENE00008028
caenorhabditis_elegans		WBGENE00008029
caenorhabditis_elegans		WBGENE00008030
caenorhabditis_elegans		WBGENE00008625
caenorhabditis_elegans		WBGENE00009891
caenorhabditis_elegans		WBGENE00009895
caenorhabditis_elegans		WBGENE00009896
caenorhabditis_elegans		WBGENE00012816
caenorhabditis_elegans		WBGENE00013971
caenorhabditis_elegans		WBGENE00013972
caenorhabditis_elegans		WBGENE00015246
caenorhabditis_elegans		WBGENE00017055
caenorhabditis_elegans		WBGENE00017183
caenorhabditis_elegans		WBGENE00019178
caenorhabditis_elegans		WBGENE00019179
caenorhabditis_elegans		WBGENE00021780

Paralogs (13): R3HDML (ENSG00000101074), CRISPLD2 (ENSG00000103196), CRISPLD1 (ENSG00000121005), GLIPR2 (ENSG00000122694), CRISP2 (ENSG00000124490), CRISP1 (ENSG00000124812), PI15 (ENSG00000137558), GLIPR1 (ENSG00000139278), CLEC18B (ENSG00000140839), CLEC18A (ENSG00000157322), CLEC18C (ENSG00000157335), GLIPR1L1 (ENSG00000173401), GLIPR1L2 (ENSG00000180481)

Protein

Protein identifiers

Cysteine-rich secretory protein 3 — P54108 (reviewed: P54108)

Alternative names: Specific granule protein of 28 kDa

All UniProt accessions (3): P54108, I3L0A1, J3KPA1

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with A1BG.

Subcellular location. Secreted.

Tissue specificity. Salivary gland, pancreas and prostate > epididymis, ovary, thymus and colon.

Similarity. Belongs to the CRISP family.

Isoforms (3)

UniProt ID	Names	Canonical?
P54108-1	1	yes
P54108-2	2
P54108-3	3

RefSeq proteins (3): NP_001177915, NP_001355052, NP_006052* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001283	CRISP-related	Family
IPR003582	ShKT_dom	Domain
IPR013871	Cysteine_rich_secretory	Domain
IPR014044	CAP_dom	Domain
IPR018244	Allrgn_V5/Tpx1_CS	Conserved_site
IPR034117	SCP_CRISP	Domain
IPR035940	CAP_sf	Homologous_superfamily
IPR042076	Crisp-like_dom	Homologous_superfamily

Pfam: PF00188, PF08562

UniProt features (16 total): disulfide bond 5, splice variant 2, sequence variant 2, sequence conflict 2, domain 2, signal peptide 1, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P54108-F1	92.65	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 191–198, 194–203, 207–240, 216–234, 225–238

Glycosylation sites (1): 239

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 116 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, GOZGIT_ESR1_TARGETS_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, chr6p12, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, HANSON_HRAS_SIGNALING_VIA_NFKB, BRUNO_HEMATOPOIESIS, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, GOCC_SECRETORY_VESICLE, GOCC_VESICLE_LUMEN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP

GO Biological Process (2): defense response (GO:0006952), innate immune response (GO:0045087)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), specific granule lumen (GO:0035580), specific granule (GO:0042581), tertiary granule lumen (GO:1904724), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
response to stress	1
immune response	1
defense response to symbiont	1
binding	1
external encapsulating structure	1
secretory granule lumen	1
specific granule	1
secretory granule	1
intracellular organelle lumen	1
tertiary granule	1

Protein interactions and networks

STRING

1088 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CRISP3	A1BG	P04217	920
CRISP3	MTDH	Q86UE4	758
CRISP3	MSMB	P08118	720
CRISP3	IL4I1	Q96RQ9	621
CRISP3	PLB1	Q6P1J6	619
CRISP3	LTA4H	P09960	548
CRISP3	LCN2	P30150	527
CRISP3	PLA2G2A	P14555	507
CRISP3	ACHE	P22303	504
CRISP3	PGLYRP1	O75594	478
CRISP3	BPIFB1	Q8TDL5	466
CRISP3	OLFM4	Q6UX06	465
CRISP3	CEBPB	P17676	455
CRISP3	FGFBP1	Q14512	442
CRISP3	QPCT	Q16769	424
CRISP3	NPPC	P23582	424

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CRISP3	ADD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): A1BG (Affinity Capture-MS), CRISP3 (Affinity Capture-MS), GPR152 (Two-hybrid), ADD2 (Affinity Capture-MS), ADD3 (Affinity Capture-MS), SLC2A8 (Affinity Capture-MS), HSPA1A (Affinity Capture-MS), CRISP3 (Phenotypic Suppression), CRISP3 (Phenotypic Suppression), CRISP3 (Phenotypic Suppression), CRISP3 (Phenotypic Suppression), MSMB (Reconstituted Complex), CRISP3 (Affinity Capture-MS), CRISP3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D3QS98, A0A0D3QS99, A2A5I3, O19010, O19011, O42596, P01137, P04202, P04629, P07200, P09533, P16562, P17246, P18341, P35739, P50414, P54108, P54831, P57110, Q01974, Q38HS2, Q3KPV7, Q3UFB7, Q505J3, Q5R7Y0, Q5T4F7, Q60477, Q658N2, Q6UWX4, Q7T141, Q7TSQ1, Q80XH4, Q8BG58, Q91009, Q99JR5, Q9CXM0, Q9D2G9, Q9EQT5, Q9GZM7, Q9H3Y0

Diamond homologs: A0A182GL09, A0A1S4EWW7, A0A218QX58, A1BQQ5, A6MFK9, A6QLZ7, A8S6B6, A9QQ26, A9YME1, B2MVK7, B9URJ1, C0ITL3, D4B327, D4P2Y4, F8J2D4, G3CJR9, O19010, O43692, P0CB15, P0DMB9, P0DMT4, P0DPU0, P0DPU1, P0DPU2, P0DPU5, P0DPV2, P0DSI3, P10736, P10737, P12020, P16562, P16563, P35759, P35760, P35778, P35779, P35780, P35781, P35782, P35783

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1005 predictions. Top by Δscore:

Variant	Effect	Δscore
6:49731249:CCA:C	acceptor_gain	1.0000
6:49731250:CAC:C	acceptor_gain	1.0000
6:49731252:C:CC	acceptor_gain	1.0000
6:49733850:T:A	acceptor_loss	1.0000
6:49735499:CATA:C	donor_gain	1.0000
6:49735500:ATAC:A	donor_loss	1.0000
6:49735501:TACT:T	donor_loss	1.0000
6:49735502:A:AC	donor_gain	1.0000
6:49735503:C:CG	donor_gain	1.0000
6:49735503:CTTGT:C	donor_gain	1.0000
6:49735587:CATTC:C	acceptor_gain	1.0000
6:49735589:TTC:T	acceptor_gain	1.0000
6:49735590:TC:T	acceptor_gain	1.0000
6:49735591:CC:C	acceptor_gain	1.0000
6:49735592:C:CA	acceptor_loss	1.0000
6:49735592:C:CC	acceptor_gain	1.0000
6:49735593:T:A	acceptor_loss	1.0000
6:49736390:CCAT:C	donor_gain	1.0000
6:49731161:A:AC	donor_gain	0.9900
6:49731162:C:CC	donor_gain	0.9900
6:49731162:CTG:C	donor_gain	0.9900
6:49731250:CA:C	acceptor_gain	0.9900
6:49731259:T:C	acceptor_gain	0.9900
6:49731259:T:TC	acceptor_gain	0.9900
6:49731923:ATCT:A	donor_gain	0.9900
6:49731924:T:C	donor_gain	0.9900
6:49733187:ATAC:A	donor_loss	0.9900
6:49733188:TACT:T	donor_loss	0.9900
6:49733189:ACTT:A	donor_loss	0.9900
6:49733190:C:CT	donor_loss	0.9900

AlphaMissense

1703 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000128570 (6:49730240 A>G), RS1000204340 (6:49739207 A>C), RS1001513815 (6:49741623 T>G), RS1001599520 (6:49743055 T>A), RS1001632082 (6:49742737 G>C), RS1001680230 (6:49730270 C>G), RS1001752562 (6:49742844 G>A), RS1001934764 (6:49741581 A>G), RS1001965925 (6:49741249 C>G,T), RS1001979761 (6:49729131 A>G), RS1002144627 (6:49732974 T>C), RS1002146143 (6:49734949 A>G), RS1002194294 (6:49736327 T>A), RS1002498564 (6:49735302 G>A), RS1002815802 (6:49746051 A>G)

Disease associations

OMIM: gene MIM:618062 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, increases mutagenesis	2
Nickel	decreases expression	2
sodium arsenite	decreases expression	1
CGP 52608	affects binding, increases reaction	1
rofecoxib	increases expression	1
enzalutamide	decreases expression	1
Arsenicals	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Lipopolysaccharides	increases expression	1
Malathion	decreases expression	1
N-Nitrosopyrrolidine	increases expression	1
Dihydrotestosterone	increases expression	1
Tetrachlorodibenzodioxin	increases expression, affects cotreatment	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.